Steps in this run
| Step |
Calls |
Tokens in |
Cache hit |
Cost |
|
ranking
|
2 |
124,072 |
|
$0.75326 |
|
response generation
|
3 |
6,222 |
|
$0.03283 |
|
haiku prescreen
|
2 |
11,843 |
|
$0.01585 |
|
learning engine pattern analysis
|
1 |
13,223 |
|
$0.01508 |
|
learning engine self eval
|
1 |
5,220 |
|
$0.00931 |
All 9 API calls — tap to expand
$0.013778
Est. cost (USD)
Result preview
```json
[
{
"post_index": 2,
"cluster_ids": [4, 21],
"claim": "AI-designed antibody molecules compress preclinical discovery timelines dramatically",
"argument_type": "empirical_claim",
"stance": "neutral_analysis",
"hyde_excerpt": "Amazon Bio Discovery's collaboration with Memorial Sloan Kettering demonstrates how AI-driven molecular design compresses traditional discove
88,141
Tokens in (billed)
$0.481357
Est. cost (USD)
Result preview
```json
[
{
"post_index": 21,
"matched_article_id": 512,
"match_confidence": 92,
"match_reason": "Tweet cites the exact MSK collaboration data point (300K antibody candidates designed, 100K tested by Twist, timeline compressed from a year to weeks) that Article 512 uses as its primary evidence for how Amazon Bio Discovery collapses the in silico-to-wet-lab handoff and disrupts CR
$0.011223
Est. cost (USD)
Result preview
The 300,000 to 100,000 funnel is the part people keep glossing over. That's not just speed, that's a structural compression of the in silico to wet lab handoff, which has historically been where institutional knowledge goes to die between siloed CRO partners.
What I couldn't stop thinking about when I wrote about Bio Discovery is that Twist is already integrated into the platform. So the question
$0.009846
Est. cost (USD)
Result preview
The 500% variance in negotiated rates for the same MRI at the same facility across different commercial insurers tells you that cash pricing isn't a discount, it's closer to the floor that insurers already knew existed and chose not to pass through.
The markup isn't a billing error. It's the product.
What I'd push further on is that the real leverage point isn't individual cash-pay savings, it's
$0.011757
Est. cost (USD)
Result preview
The patent expiration problem runs deeper than lost interest. What expires is the monopoly on manufacturing, but the knowledge of what those molecules do across 40-50 targets doesn't disappear. It gets orphaned. No one funds the repositioning trials because no one can price-protect the outcome.
The Revlimid story actually shows this from the other direction. Celgene spent roughly $800 million dev
$0.002076
Est. cost (USD)
Result preview
```json
[]
```
32,558
Tokens in (billed)
$0.271902
Est. cost (USD)
Result preview
[]
$0.009312
Est. cost (USD)
Result preview
```json
[
{"post_index": 0, "prediction": "reject", "confidence": 92, "reason": "Vague retweet with no substantive healthcare content or claim; lacks analytical context"},
{"post_index": 1, "prediction": "reject", "confidence": 95, "reason": "Political/personal anecdote unrelated to healthcare;
13,223
Tokens in (billed)
$0.015082
Est. cost (USD)
Result preview
```json
[
{
"category": "ai_safety_cybersecurity_incident_tangential",
"summary": "Posts about AI safety incidents, security vulnerabilities, or data breaches that lack healthcare-specific context or systemic analysis.",
"exclusion_rule": "Exclude posts reporting AI model safety failur